ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
Dow Jones
38.589,16
-0,15%
Euro vs US Dollar
1,07215
-0,01%
Bitcoin
66.299,67
0,45%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. REGENXBIO Inc (RGNX)

  7. REGENXBIO Inc (RGNX) News

RGNX

REGENXBIO (RGNX)

REGENXBIO Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:RGNX
DatumZeitQuelleÜberschriftSymbolFirma
12/06/202413h05PR Newswire (US)REGENXBIO Announces Leadership TransitionNASDAQ:RGNXREGENXBIO Inc
05/06/202413h05PR Newswire (US)REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:RGNXREGENXBIO Inc
04/06/202422h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGNXREGENXBIO Inc
04/06/202422h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGNXREGENXBIO Inc
04/06/202422h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGNXREGENXBIO Inc
04/06/202422h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGNXREGENXBIO Inc
03/06/202422h35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGNXREGENXBIO Inc
16/05/202423h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGNXREGENXBIO Inc
14/05/202422h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RGNXREGENXBIO Inc
10/05/202413h05PR Newswire (US)REGENXBIO to Participate in Upcoming Investor ConferencesNASDAQ:RGNXREGENXBIO Inc
08/05/202422h16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RGNXREGENXBIO Inc
08/05/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGNXREGENXBIO Inc
08/05/202422h05PR Newswire (US)REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational HighlightsNASDAQ:RGNXREGENXBIO Inc
01/05/202413h05PR Newswire (US)REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational HighlightsNASDAQ:RGNXREGENXBIO Inc
24/04/202413h05PR Newswire (US)REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitNASDAQ:RGNXREGENXBIO Inc
28/03/202412h05PR Newswire (US)REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMDNASDAQ:RGNXREGENXBIO Inc
27/03/202421h05PR Newswire (US)REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy DaysNASDAQ:RGNXREGENXBIO Inc
11/03/202413h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGNXREGENXBIO Inc
11/03/202412h05PR Newswire (US)REGENXBIO to Participate in Upcoming Investor ConferencesNASDAQ:RGNXREGENXBIO Inc
08/03/202412h09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RGNXREGENXBIO Inc
08/03/202400h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGNXREGENXBIO Inc
07/03/202412h03Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:RGNXREGENXBIO Inc
07/03/202405h20PR Newswire (US)REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded WarrantsNASDAQ:RGNXREGENXBIO Inc
06/03/202422h23Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RGNXREGENXBIO Inc
06/03/202422h10PR Newswire (US)REGENXBIO Announces Proposed Public Offering of Common StockNASDAQ:RGNXREGENXBIO Inc
05/03/202422h26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RGNXREGENXBIO Inc
05/03/202413h05PR Newswire (US)REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIALNASDAQ:RGNXREGENXBIO Inc
29/02/202422h57PR Newswire (US)REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® TrialNASDAQ:RGNXREGENXBIO Inc
27/02/202422h54Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RGNXREGENXBIO Inc
27/02/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGNXREGENXBIO Inc
 Showing the most relevant articles for your search:NASDAQ:RGNX

Kürzlich von Ihnen besucht

TG
ALV
Allianz
TG
D7G
Nel ASA
DBI
DAX
DAX
CCOM
US500
US 500
USOTC
ADDYY
Adidas (QX)
AMEX
XLF
Financial Select Sector
COIN
ETHUSD
Ethereum
NASDAQ
AMZN
Amazon.com
TG
TUI1
Tui
CCOM
US100
US Tech 100
TG
DTE
Deutsche Telekom
NYSE
XOM
Exxon Mobil
FX
EURJPY
Euro vs Yen
NYSE
KO
Coca Cola
USOTC
BASFY
BASF (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten